RESUMO
Viral infections contribute to approximately 12% of cancers worldwide, with the vast majority occurring in developing countries and areas. Two DNA viruses, Epstein-Barr virus (EBV) and human papillomavirus (HPV), are associated with 38% of all virus-associated cancers. The probability of one patient infected with these two distinct types of viruses is increasing. Here, we summarize the co-infection of EBV and HPV in human malignancies and address the possible mechanisms for the co-infection of EBV and HPV during tumorigenesis.
Assuntos
Coinfecção/epidemiologia , Infecções por Vírus Epstein-Barr/epidemiologia , Neoplasias/virologia , Infecções por Papillomavirus/epidemiologia , Desaminases APOBEC , Coinfecção/genética , Coinfecção/prevenção & controle , Coinfecção/virologia , Citidina Desaminase , Citosina Desaminase/genética , Infecções por Vírus Epstein-Barr/genética , Infecções por Vírus Epstein-Barr/prevenção & controle , Feminino , Regulação Neoplásica da Expressão Gênica , Humanos , Masculino , Neoplasias/genética , Infecções por Papillomavirus/genética , Infecções por Papillomavirus/prevenção & controle , Vacinas Virais/uso terapêuticoRESUMO
An ultra-high performance liquid chromatography tandem mass spectrometry (U-HPLC-MS/MS) method was developed and validated to determine liensinine and isoliensinine in rat plasma simultaneously. Plasma samples were prepared using protein precipitation with acetonitrile. The two analytes and the internal standard pirfenidone were separated on an Acquity U-HPLC BEH C18 column with the mobile phase of acetonitrile and 1% formic acid in water with gradient elution at a flow rate of 0.40mL/min. Both liensinine and isoliensinine were eluted at 0.63 and 0.82min, respectively. The detection was performed on a triple quadrupole tandem mass spectrometer equipped with positive-ion electrospray ionization (ESI) by multiple reactions monitoring (MRM) of the transitions at m/z 611.6 â 206.2 for liensinine and m/z 611.4 â 192.2 for isoliensinine. The linearity of this method was found to be within the concentration range of 5-700ng/mL for liensinine and isoliensinine in rat plasma. The lower limits of quantification (LLOQ) were all 5ng/mL for liensinine and isoliensinine. The relative standard deviations (RSD) of intra and inter precision were less than 10% for both liensinine and isoliensinine. The method was also successfully applied to the pharmacokinetic study of liensinine and isoliensinine in rats.